NCT02994576View on ClinicalTrials.gov

Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 12, 2016

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Nonsmall Cell Lung Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab, 1200 mg administered I.V. once

Trial Locations (3)

94805

Gustave Roussy, Villejuif

Unknown

Centre Hospitalier de Chauny, Chauny

Centre Marie Lannelongue, Le Plessis-Robinson

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT02994576 - Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter